1887
Rapid communication Open Access
Like 0

Abstract

For the period of predominance of SARS-CoV-2 Omicron variant in Slovenia, February to March 2022, we estimated mRNA vaccine effectiveness (VE) against severe acute respiratory infection (SARI) COVID-19 using surveillance data. In the most vulnerable age group comprising individuals aged 65 years and more, VE against SARI COVID-19 was 95% (95% CI: 95–96%) for those vaccinated with three doses, in comparison to 82% (95% CI: 79–84%) for those vaccinated with two doses. Such levels of protection were maintained for at least 6 months.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2022.27.20.2200350
2022-05-19
2022-06-30
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2022.27.20.2200350
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/27/20/eurosurv-27-20-3.html?itemId=/content/10.2807/1560-7917.ES.2022.27.20.2200350&mimeType=html&fmt=ahah

References

  1. Grgič Vitek M, Klavs I, Učakar V, Serdt M, Mrzel M, Vrh M, et al. Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021. Euro Surveill. 2022;27(1):2101110.  https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101110  PMID: 34991780 
  2. National Laboratory of Health, Environment and Food (NLZOH). Sledenje različicam SARS CoV-2. [Surveillance of variants of SARS_CoV-2]. Available from: https://www.nlzoh.si/objave/sledenje-razlicicam-sars-cov-2-45/
  3. Klavs I, Serdt M, Učakar V, Grgič-Vitek M, Fafangel M, Mrzel M, et al. , EPISARI Network, Members of the EPISARI Network. Enhanced national surveillance of severe acute respiratory infections (SARI) within COVID-19 surveillance, Slovenia, weeks 13 to 37 2021. Euro Surveill. 2021;26(42):2100937.  https://doi.org/10.2807/1560-7917.ES.2021.26.42.2100937  PMID: 34676822 
  4. National institute of Public Health (NIJZ). Elektronski register cepljenih oseb in neželenih učinkov po cepljenju. [Electronic Registry of vaccinated individuals and adverse events following vaccinations]. Ljubljana: NIJZ. [Accessed: 2 Dec 2021]. Available from: https://www.nijz.si/sl/elektronski-register-cepljenih-oseb-in-nezelenih-ucinkov-po-cepljenju-erco
  5. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. , COVID-19 Genomics UK (COG-UK) consortium. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303-12.  https://doi.org/10.1016/S0140-6736(22)00462-7  PMID: 35305296 
  6. EMA and ECDC. COVID-19: Joint statement from ECDC and EMA on the administration of a fourth dose of mRNA vaccines. Stockholm: ECDC; Amsterdam: EMA. Available from: https://www.ema.europa.eu/en/documents/public-statement/covid-19-joint-statement-ecdc-ema-administration-fourth-dose-mrna-vaccines_.pdf
  7. Hansen CH, Schelde AB, Moustsen-Helm IR, Emborg HD, Krause TG, Mølbak K, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. Available from: https://www.medrxiv.org/content/10.1101/2021.12.20.21267966v3
  8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022: Epub ahead of print.  https://doi.org/10.1038/s41591-022-01753-y  PMID: 35189624 
  9. Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399(10325):625-6.
  10. Collie S, Champion J, Moultrie H, Bekker LG, Gray G. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med. 2022;386(5):494-6.  https://doi.org/10.1056/NEJMc2119270  PMID: 34965358 
  11. Baum U, Poukka E, Leino T, Kilpi T, Nohynek H, Palmu AA. High vaccine effectiveness against severe Covid-19 in the elderly in Finland before and after the emergence of Omicron. medRxiv. 2022.03.11.22272140; doi:
  12. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):255-63.  https://doi.org/10.15585/mmwr.mm7107e2  PMID: 35176007 
  13. Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. medRxiv. doi:  https://doi.org/10.1101/2022.03.13.22272308 
/content/10.2807/1560-7917.ES.2022.27.20.2200350
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error